Advanced in Type 2 Diabetes (T2D)

Dr. Souheil Moussly

Internal Medicine
3890 Turtle Creek Dr, 
Port Orange, FL 
Accepting New Patients
Advanced in Type 2 Diabetes (T2D)
3890 Turtle Creek Dr, 
Port Orange, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Souheil Moussly is a primary care provider, practicing in Internal Medicine in Port Orange, Florida. Dr. Moussly is rated as an Advanced provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Enlarged Prostate (BPH), Hypertension, Familial Hypertension, and Glucocorticoid-Remediable Aldosteronism. Dr. Moussly is currently accepting new patients.

His clinical research consists of participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Arabic
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

3890 Turtle Creek Dr, Port Orange, FL 32129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 4 Less Clinical Trials
Similar Doctors
Distinguished in Type 2 Diabetes (T2D)
Dr. Mark G. Brooks
Internal Medicine
Distinguished in Type 2 Diabetes (T2D)
Dr. Mark G. Brooks
Internal Medicine

Mark G Brooks M D P A

10000 W Colonial Dr, Suite 187, 
Ocoee, FL 
 (50.8 miles away)
407-578-6610
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Brooks is a primary care provider, practicing in Internal Medicine in Ocoee, Florida. Dr. Brooks is rated as a Distinguished provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Type 2 Diabetes (T2D), Heart Murmurs, Glucocorticoid-Remediable Aldosteronism, and Familial Hypertension. Dr. Brooks is currently accepting new patients.

Distinguished in Type 2 Diabetes (T2D)
Dr. Jaime C. Gonzalez
Internal Medicine
Distinguished in Type 2 Diabetes (T2D)
Dr. Jaime C. Gonzalez
Internal Medicine

Orlando Family Physicians LLC

1130 S Semoran Blvd, 
Orlando, FL 
 (45.1 miles away)
407-382-1376
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jaime Gonzalez is a primary care provider, practicing in Internal Medicine in Orlando, Florida. Dr. Gonzalez is rated as a Distinguished provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Hypertensive Heart Disease, Pediatric Myocarditis, Necrosis, and Enlarged Liver. Dr. Gonzalez is currently accepting new patients.

Distinguished in Type 2 Diabetes (T2D)
Dr. Syed Mumtaz
Internal Medicine
Distinguished in Type 2 Diabetes (T2D)
Dr. Syed Mumtaz
Internal Medicine
724 W Vine St, 
Kissimmee, FL 
 (61.8 miles away)
407-944-4450
Languages Spoken:
English
See accepted insurances

Syed Mumtaz is a primary care provider, practicing in Internal Medicine in Kissimmee, Florida. Dr. Mumtaz is rated as a Distinguished provider by MediFind in the treatment of Type 2 Diabetes (T2D). His top areas of expertise are Hypertensive Heart Disease, Osteomyelitis in Children, Enlarged Liver, and Type 2 Diabetes (T2D).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moussly's expertise for a condition
ConditionClose
      View All 87 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile